Login to Your Account


Auspex Pharmaceuticals, Uniqure, Genocea Biosciences price IPOs; hot market continues

By Jennifer Boggs
Managing Editor

Thursday, February 6, 2014

The good news is that the initial public offering (IPO) market keeps looking good for biopharma, as three more firms priced Wednesday, with two of those, both rare disease firms, pricing at the high end or above their proposed ranges. That makes nine IPOs so far this year; in comparison, only six IPOs had priced during the first four months of 2013, which turned out to be a record-breaking year for biopharma IPOs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription